目的 探討益心通脈顆粒聯(lián)合貝尼地平治療冠心病心絞痛的臨床療效。方法 選取2018年11月—2020年11月在鄭州市第一人民醫(yī)院治療的112例冠心病心絞痛患者，根據(jù)隨機數(shù)字表法分為對照組（56例）和治療組（56例）。對照組飯后口服鹽酸貝尼地平片，1片/次，2次/d。治療組在對照組基礎(chǔ)上口服益心通脈顆粒，1包/次，3次/d。兩組連續(xù)治療14 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀好轉(zhuǎn)時間，心絞痛發(fā)作情況，血清炎性因子白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、超敏C反應(yīng)蛋白（hs-CRP）和細(xì)胞間黏附分子1（ICAM-1）水平及不良反應(yīng)情況。結(jié)果 治療后，治療組患者總有效率明顯高于對照組（P<0.05）；治療后，治療組患者癥狀好轉(zhuǎn)時間均早于對照組（P<0.05）。治療后，兩組患者心絞痛發(fā)作頻率、每次發(fā)作持續(xù)時間明顯降低（P<0.05），且治療組患者均明顯低于對照組（P<0.05）。治療后，兩組患者血清炎性因子IL-6、TNF-α、hs-CRP、ICAM-1水平均明顯降低（P<0.05），且治療組患者明顯低于對照組（P<0.05）。治療組患者不良反應(yīng)發(fā)生率明顯低于對照組（P<0.05）。結(jié)論 益心通脈顆粒與貝尼地平聯(lián)合治療后，可有效改善冠心病心絞痛患者臨床癥狀，降低血脂及炎性水平，且藥物安全有效。

Objective To explore the clinical efficacy of Yixin Tongmai Granules combined with benidipine in treatment of angina pectoris of coronary heart disease. Methods Patients (112 cases) with angina pectoris of coronary heart disease in the First People’s Hospital of Zhengzhou from November 2018 to November 2020 were divided into control (56 cases) and treatment (56 cases) groups according to the table of random numbers. Patients in the control group were po administered with Benidipine Hydrochloride Tablets after meals, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Yixin Tongmai Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, attack of angina pectoris, the serum inflammatory factor of IL-6, TNF-α, hs-CRP and ICAM-1 levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the total clinical effective rate of the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the improvement time of symptom in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the frequency and duration of angina pectoris in the two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of serum inflammatory factors IL-6, TNF-α, hs-CRP and ICAM-1 in the two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion The combined treatment of Yixin Tongmai Granules and benidipine can effectively improve the clinical symptoms of patients with angina pectoris of coronary heart disease, reduce blood lipids and inflammatory levels, and the drugs are safe and effective.

R975

河南省醫(yī)學(xué)科技攻關(guān)計劃（聯(lián)合共建）項目（LHCJ20190991）